The treatment, donanemab, which will be sold under the brand name Kisunla, was shown to modestly slow the cognitive decline associated with the disease.
Advertisement
STAT+
Your go-to source for the world of life sciences, medicine, and biopharma. Subscribe now.Cancel anytime.
Subscribe nowMore From STAT
More From STAT
More From STAT
STAT offers a variety of in-person and virtual events throughout the year.
All Events
09
Jul
Virtual July 9, 2024
The immune-checkpoint inhibitor market alone was worth $15.5B in 2023. But could new diagnostics help it exceed its $53.5B predicted value in 2025? Here, AI is becoming a powerful tool. So will all drugs soon come with their own AI diagnostics? Who will fund their creation and distribution? And what is the clinical appetite for […]
16
Oct
Boston, MA
More From STAT
More From STAT
More From STAT
We create tools to help you understand and track complex areas of development.
All Trackers
Here are the dozens of weight loss drugs in development to catch a booming market.
Follow the latest developments in genome editing.
A guide to the health systems and companies driving adoption.
An authoritative database of FDA’s fast-tracked medical devices.
Mon - Fri
Your daily dose of news in health and science
Our Picks
Our Picks
STAT’s selection of must-read stories and investigations
coercive care
coercive care
